Program

The 22nd Annual Scientific Meeting of the Heart Failure Society of America will be held on Saturday, September 15, through Tuesday, September 18, 2018 at the Gaylord Opryland in Nashville, TN.

Target Audience: HFSA’s Annual Scientific Meeting is intended for physicians, nurses, nurse practitioners, pharmacists,  scientists, and health care professionals who specialize or have an interest  in heart failure.

Note: Program is subject to change and will be updated continuously up to the conference.

JUMP TO
Program Highlights
Industry Expert Theaters (Non-CME)
Contemporary Forums (Non-CME)

Program Highlights

Industry Expert Theaters (Non-CME)

Sunday, September 15, 2018
  • Iron Deficiency Anemia (IDA) in Patients with Heart Failure
    6:15 PM – 7:15 PM
    Supported by Daiichi Sankyo
    Details
    Faculty
    Nassir Azimi, MD
    Description
    The program will address the following:
    •  Types of patients who can have iron deficiency anemia (IDA) and its prevalence
    •  Pathophysiology, causes and consequences of IDA
    •  Impact of IDA in patients with heart failure
    • Differential diagnosis of IDA using laboratory assessments, signs and symptoms
    • The treatment goals and available treatments for IDA
    • Efficacy and safety of Injectafer® (ferric carboxymaltose injection) in patients with IDA
Sunday, September 16, 2018
  • Problems and Optimization of Volume Management in Patients with Acute Heart Failure
    10:00 AM – 10:30 AM
    Supported by RenalGuard Solutions, Inc.
    Details
    Faculty
    Howard Levin, MD
    Description
    Diuretic resistance remains a challenge and concern in the treatment of acute decompensated heart failure. Several leading experts in cardiology will review the latest understanding of the causes of diuretic resistance and discuss late breaking results on methods to increase urine output in acute decompensated heart failure patients.
  • Bridging Perspectives: Insights on Cardiorenal Interactions in Patients With Heart Failure
    12:00 PM – 1:00 PM
    Supported by Novartis
    Details
    Faculty
    Jeffrey Testani, MD, MTR
    Hamid Moradi MD, FACP, FASN
    Description
    In both chronic heart failure and episodes of acute decompensation, cardiac and renal pathophysiologic mechanisms interact bidirectionally, resulting in altered hemodynamics, activation of the renin angiotensin-aldosterone system and sympathetic nervous system, and reduced effectiveness of the natriuretic peptide system. Renal dysfunction is common in patients with heart failure, and therefore thoughtful management of cardiorenal interactions is important for the prevention of further organ dysfunction and disease progression. This program will review cardiorenal interactions in the pathophysiology of heart failure from the perspective of both a cardiologist and nephrologist, discuss the management of cardiorenal syndrome in inpatient and outpatient settings, and highlight the importance of multidisciplinary care for patients with heart failure and kidney dysfunction.
  • Considering Heart Rate in Managing HF Hospitalization
    1:30 PM – 2:00 PM
    Details
    Faculty
    Gregg C. Fonarow, MD, FHFSA
    Description
    Disease state education on considering heart rate in managing heart failure hospitalization.
Monday, September 17, 2018
  • HFrEF and Sudden Cardiac Death: Insights from the PARADIGM Study
    12:00 PM – 1:00 PM
    Supported by Novartis Pharmaceuticals Corporation
    Details
    Faculty
    Richard Wright, MD, FACC
    Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FAAN (pending confirmation)
    Description
    Current understanding of heart failure pathophysiology suggests that an imbalance in the neurohormonal systems drives development and progression of heart failure. Although there are evidence-based pharmacologic therapies that target the sympathetic nervous system or the renin-angiotensin-aldosterone system, morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF) remain high. Please join us as medical experts engage in discussions on the mechanism of action of a novel HFrEF therapy and its landmark clinical trial data. This session will also allow for the practical application of the HF guideline and clinical study findings through the use of an interactive patient case study.
 

Contemporary Forums (Non-CME)

Saturday, September 15, 2018
  • Third Annual: Managing the Economic Challenges in the Treatment of HF
    8:00 AM – 10:00 AM
    Supported by Cytokinetics
  • The Use of MCS in Cardiogenic Shock Patients
    12:15 PM – 1:15 PM
    Supported by Abiomed
Monday, September 17
  • Improving Heart Failure Patient Care Across the Continuum
    7:15 AM – 8:15 AM
    Supported by Medtronic